BRPI0611409B8 - preparação oral compreendendo lurasidona - Google Patents

preparação oral compreendendo lurasidona

Info

Publication number
BRPI0611409B8
BRPI0611409B8 BRPI0611409A BRPI0611409A BRPI0611409B8 BR PI0611409 B8 BRPI0611409 B8 BR PI0611409B8 BR PI0611409 A BRPI0611409 A BR PI0611409A BR PI0611409 A BRPI0611409 A BR PI0611409A BR PI0611409 B8 BRPI0611409 B8 BR PI0611409B8
Authority
BR
Brazil
Prior art keywords
preparation
lurasidone
water
oral preparation
oral
Prior art date
Application number
BRPI0611409A
Other languages
English (en)
Portuguese (pt)
Inventor
Fujihara Kazuyuki
Original Assignee
Dainippon Sumitomo Pharma Co
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0611409(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co, Sumitomo Dainippon Pharma Co Ltd filed Critical Dainippon Sumitomo Pharma Co
Publication of BRPI0611409A2 publication Critical patent/BRPI0611409A2/pt
Publication of BRPI0611409A8 publication Critical patent/BRPI0611409A8/pt
Publication of BRPI0611409B1 publication Critical patent/BRPI0611409B1/pt
Publication of BRPI0611409B8 publication Critical patent/BRPI0611409B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0611409A 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona BRPI0611409B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-153508 2005-05-26
JP2005153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja) 2005-05-26 2006-05-26 医薬品組成物

Publications (4)

Publication Number Publication Date
BRPI0611409A2 BRPI0611409A2 (pt) 2010-11-23
BRPI0611409A8 BRPI0611409A8 (pt) 2015-12-15
BRPI0611409B1 BRPI0611409B1 (pt) 2020-12-29
BRPI0611409B8 true BRPI0611409B8 (pt) 2021-05-25

Family

ID=37452103

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0611409A BRPI0611409B8 (pt) 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona
BR122020005056-0A BR122020005056B1 (pt) 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020005056-0A BR122020005056B1 (pt) 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)

Country Status (22)

Country Link
US (5) US8729085B2 (OSRAM)
EP (2) EP1884242B1 (OSRAM)
JP (2) JP4733120B2 (OSRAM)
KR (2) KR101380088B1 (OSRAM)
CN (2) CN102048734B (OSRAM)
AU (1) AU2006250340C1 (OSRAM)
BE (1) BE2014C057I2 (OSRAM)
BR (2) BRPI0611409B8 (OSRAM)
CA (1) CA2606510C (OSRAM)
CY (2) CY1114118T1 (OSRAM)
DK (2) DK2422783T3 (OSRAM)
ES (2) ES2535478T3 (OSRAM)
FR (1) FR14C0069I2 (OSRAM)
HU (1) HUS1400051I1 (OSRAM)
LU (1) LU92550I2 (OSRAM)
MX (1) MX2007014872A (OSRAM)
NL (1) NL300690I2 (OSRAM)
PL (1) PL1884242T3 (OSRAM)
PT (1) PT1884242E (OSRAM)
RU (1) RU2398586C3 (OSRAM)
SI (1) SI1884242T1 (OSRAM)
WO (1) WO2006126681A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2633088T3 (es) * 2005-05-18 2017-09-19 Sumitomo Dainippon Pharma Co., Ltd. Comprimido estable que contiene droxidopa
DK2422783T3 (en) * 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
CN102119034B (zh) 2008-06-13 2013-05-22 大日本住友制药株式会社 在口腔中快速崩解的片剂和制备其的方法
JP5694773B2 (ja) * 2008-09-30 2015-04-01 テバ製薬株式会社 圧縮成型製剤およびその製造方法
EP3351240B1 (en) 2009-05-19 2019-04-10 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
US9433620B2 (en) * 2011-05-13 2016-09-06 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
US8981095B2 (en) 2011-07-28 2015-03-17 Mapi Pharma Ltd. Intermediate compounds and process for the preparation of lurasidone and salts thereof
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN106074414B (zh) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EP3318279A1 (en) * 2016-11-02 2018-05-09 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of lurasidone hydrochloride
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
AU2018317472A1 (en) * 2017-08-18 2020-03-05 Abbvie Inc. Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja) 2018-02-28 2019-09-06 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
PL3772992T3 (pl) 2018-04-10 2022-10-31 Freshfoodz Gmbh Sposób konserwowania posiłku przygotowanego przez podgrzewanie i dostarczania żywienia zbiorowego
JP7585043B2 (ja) * 2018-04-13 2024-11-18 サムヤン ホールディングス コーポレイション レナリドミドを含む医薬組成物
EP4035733A4 (en) * 2019-09-25 2024-01-10 Nobelpharma Co., Ltd. Granule having masked unpleasant taste and method for producing same
CN115843243B (zh) * 2020-08-26 2025-09-05 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
MX2023007601A (es) 2020-12-23 2023-07-10 Sumitomo Pharma Co Ltd Preparacion solida oral.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
DE69624559T2 (de) 1995-02-28 2003-07-10 Aventis Pharmaceuticals Inc., Bridgewater Arzneizubereitungen für piperidinalkanolderivate
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
ES2242298T3 (es) 1997-10-20 2005-11-01 Dainippon Pharmaceutical Co., Ltd. Composicion medicamentos de disolucion rapida que contiene as-3201.
JP4063386B2 (ja) * 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
WO2001076557A1 (en) * 2000-04-10 2001-10-18 Sumitomo Pharmaceuticals Co., Ltd. Sustained release preparations
ES2325764T3 (es) * 2000-09-22 2009-09-16 Dainippon Sumitomo Pharma Co., Ltd. Preparaciones orales con buenas caracteristicas de desintegracion.
ATE468325T1 (de) 2001-03-19 2010-06-15 Dainippon Sumitomo Pharma Co Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE60327634D1 (de) * 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
CA2494707A1 (en) 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
WO2004078173A1 (ja) * 2003-02-05 2004-09-16 Shionogi & Co., Ltd. 溶出性の改善された錠剤
DK3395340T3 (da) 2003-09-12 2019-07-15 Amgen Inc Hurtigt opløsende formulering af cinacalcet-hcl
EP1695699A4 (en) 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
DK2422783T3 (en) 2005-05-26 2015-05-11 Sumitomo Dainippon Pharma Co Ltd pharmaceutical composition

Also Published As

Publication number Publication date
AU2006250340C1 (en) 2014-06-12
BRPI0611409A8 (pt) 2015-12-15
ES2535478T3 (es) 2015-05-12
FR14C0069I2 (fr) 2015-11-20
FR14C0069I1 (fr) 2014-10-24
US20140235651A1 (en) 2014-08-21
PL1884242T3 (pl) 2013-09-30
LU92550I2 (fr) 2015-11-02
US8883794B2 (en) 2014-11-11
BRPI0611409A2 (pt) 2010-11-23
CA2606510C (en) 2014-07-22
JP2011126915A (ja) 2011-06-30
SI1884242T1 (sl) 2013-07-31
RU2398586C2 (ru) 2010-09-10
BR122020005056A8 (pt) 2022-11-22
EP1884242A4 (en) 2009-07-01
EP1884242B1 (en) 2013-04-17
CN102048734A (zh) 2011-05-11
US9555027B2 (en) 2017-01-31
KR20080012306A (ko) 2008-02-11
US8729085B2 (en) 2014-05-20
DK2422783T3 (en) 2015-05-11
CN101184489A (zh) 2008-05-21
AU2006250340A1 (en) 2006-11-30
RU2007148997A (ru) 2009-07-10
WO2006126681A1 (ja) 2006-11-30
US20180161322A1 (en) 2018-06-14
JP4733120B2 (ja) 2011-07-27
KR20130122019A (ko) 2013-11-06
US20090143404A1 (en) 2009-06-04
BRPI0611409B1 (pt) 2020-12-29
KR101380088B1 (ko) 2014-04-10
CA2606510A1 (en) 2006-11-30
ES2408687T3 (es) 2013-06-21
BR122020005056B1 (pt) 2023-01-10
NL300690I2 (nl) 2017-11-02
MX2007014872A (es) 2008-02-15
US20150056284A1 (en) 2015-02-26
DK1884242T3 (da) 2013-05-06
BR122020005056A2 (OSRAM) 2010-11-23
AU2006250340B2 (en) 2012-02-09
HUS1400051I1 (hu) 2016-10-28
CY1114118T1 (el) 2016-06-22
HK1108379A1 (en) 2008-05-09
BE2014C057I2 (OSRAM) 2025-12-10
JP5285105B2 (ja) 2013-09-11
EP2422783B1 (en) 2015-04-08
CN101184489B (zh) 2011-01-19
US20150265611A1 (en) 2015-09-24
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
PT1884242E (pt) 2013-05-21
JPWO2006126681A1 (ja) 2008-12-25
CN102048734B (zh) 2013-11-20
RU2398586C3 (ru) 2017-10-04
EP2422783A1 (en) 2012-02-29
EP1884242A1 (en) 2008-02-06
KR101552033B1 (ko) 2015-09-09
US9907794B2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
BRPI0611409B8 (pt) preparação oral compreendendo lurasidona
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2458920C2 (ru) Новые соединения
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
MY141794A (en) Benzamide and heteroarene derivatives
DE602005018758D1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
BRPI0407097A (pt) Antagonista do casr
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
TNSN08405A1 (en) Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
JP2008110984A5 (OSRAM)
NO20092535L (no) Fumaratsalt av (alfa S, beta R)-6-brom-alfa-[2-(dimetylamino)etyl]-2-metoksy-alfa-1-naftalenyl-beta-fenyl-3-kinolinetanol
TNSN01005A1 (en) GLYBURIDE COMPOSITION
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
BRPI0513891B8 (pt) derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: THALITA DUQUE MARTINS PAES - 870210057587 - 25/06/2021

B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)